Journal of Clinical Pediatrics >
Pharmacologic and upcoming treatment of pediatric narcolepsy
Received date: 2024-12-12
Accepted date: 2025-03-07
Online published: 2025-06-01
Narcolepsy is a rare neurological disorder characterized by excessive daytime sleepiness, cataplexy, disturbed night sleep, sleep paralysis and sleep hallucinations. It typically onsets during childhood or adolescence. The treatment is focused on ameliorating clinical symptoms, encompassing drug therapy to alleviate symptoms such as excessive daytime sleepiness and cataplexy. Despite the fact that orexin replacement therapy and orexin receptor agonists are in the research stage, the majority of drugs for narcolepsy used in children are off-label. Hence, more clinical studies are requisite to validate their safety and efficacy in children.
Key words： child; narcolepsy; pharmacologic treatment
ZHANG Yixin , HONG Siqi . Pharmacologic and upcoming treatment of pediatric narcolepsy[J]. Journal of Clinical Pediatrics, 2025 , 43(6) : 475 -482 . DOI: 10.12372/jcp.2025.24e1345
| [1] | 中华医学会神经病学分会睡眠障碍学组. 中国发作性睡病诊断与治疗指南(2022版)[J]. 中华神经科杂志, 2022, 55(5): 406-420. |
| Chinese Society of Sleep Disorders. Chinese guidelines for diagnosis and treatment of Narcolepsy (2022)[J]. Zhonghua Shenjingke Zazhi, 2022, 55(5): 406-420. | |
| [2] | American Academy of Sleep Medicine. International classification of sleep disorders third edition, text revision (ICSD-3-TR)[M]. Darien, IL: American Academy of Sleep Medicine, 2023. |
| [3] | Liblau RS, Latorre D, Kornum BR, et al. The immuno-pathogenesis of narcolepsy type 1[J]. Nat Rev Immunol, 2024, 24(1): 33-48. |
| [4] | Li S, Yang J. Pitolisant for treating patients with narcolepsy[J]. Expert Rev Clin Pharmacol, 2020, 13(2): 79-84. |
| [5] | Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2017, 16(3): 200-207. |
| [6] | Meskill GJ, Davis CW, Zarycranski D, et al. Clinical impact of pitolisant on excessive daytime sleepiness and cataplexy in adults with narcolepsy: an analysis of randomized placebo-controlled trials[J]. CNS Drugs, 2021, 36(1): 61-69. |
| [7] | Dauvilliers Y, Arnulf I, Szakacs Z, et al. Long-term use of pitolisant to treat patients with narcolepsy: Harmony Ⅲ Study[J]. Sleep, 2019, 42(11): zsz174. |
| [8] | Dauvilliers Y, Lecendreux M, Lammers GJ, et al. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial[J]. Lancet Neurol, 2023, 22(4): 303-311. |
| [9] | Triller A, Pizza F, Lecendreux M, et al. Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study[J]. Sleep Med, 2023, 103: 62-68. |
| [10] | Claudio L A B. European guideline and expert statements on the management of narcolepsy in adults and children[J]. Eur J Neurol, 2021, 28(9): 2815-2830. |
| [11] | Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline[J]. J Clin Sleep Med, 2021, 17(9): 1881-1893. |
| [12] | Franceschini C, Pizza F, Cavalli F, et al. A practical guide to the pharmacological and behavioral therapy of narcolepsy[J]. Neurotherapeutics, 2021, 18(1): 6-19. |
| [13] | Steven TS. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy[J]. Sleep Med Rev, 2019, 43: 23-36. |
| [14] | Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy[J]. Ann Neurol, 1998, 43(1): 88-97. |
| [15] | Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy[J]. Curr Med Res Opin, 2006, 22(4): 761-774. |
| [16] | Lecendreux M, Bruni O, Franco P, et al. Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy[J]. J Sleep Res, 2012, 21(4): 481-483. |
| [17] | Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children[J]. Sleep Med, 2003, 4(6): 579-582. |
| [18] | Mamelak M. Sleep, narcolepsy, and sodium oxybate[J]. Curr Neuropharmacol, 2022, 20(2): 272-291. |
| [19] | Chen C, Jenkins J, Zomorodi K, et al. Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies[J]. Clin Transl Sci, 2021, 14(6): 2278-2287. |
| [20] | J B. Sodium oxybate improves excessive daytime sleepiness in narcolepsy[J]. Sleep, 2006, 29(7): 939-946. |
| [21] | Xyrem International Study G. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients[J]. Sleep Med, 2005, 6(5): 415-421. |
| [22] | Plazzi G, Ruoff C, Lecendreux M, et al. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation[J]. Lancet Child Adolesc Health, 2018, 2(7): 483-494. |
| [23] | Lecendreux M, Plazzi G, Dauvilliers Y, et al. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients[J]. J Clin Sleep Med, 2022, 18(9): 2217-2227. |
| [24] | Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy[J]. Sleep, 2021, 44(3): zsaa206. |
| [25] | Bogan RK, Foldvary-Schaefer N, Skowronski R, et al. Long-term safety and tolerability during a clinical trial and open-label extension of low-sodium oxybate in participants with narcolepsy with cataplexy[J]. CNS Drugs, 2023, 37(4): 323-335. |
| [26] | Dauvilliers Y, Roth T, Bogan R, et al. Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial[J]. Sleep, 2023, 46(11): zsad152. |
| [27] | Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy[J]. Sleep, 2022, 45(6): zsab200. |
| [28] | Zomorodi K, Chen D, Lee L, et al. A randomized, double‐blind, placebo‐ and positive‐controlled, 4‐period crossover study of the effects of solriamfetol on QTcF intervals in healthy participants[J]. Clin Pharmacol Drug Dev, 2020, 10(4): 404-413. |
| [29] | Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy[J]. Ann Neurol, 2019, 85(3): 359-370. |
| [30] | Malhotra A, Shapiro C, Pepin JL, et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea[J]. Sleep, 2020, 43(2): zsz220. |
| [31] | Winter Y, Mayer G, Kotterba S, et al. Solriamfetol real world experience study (SURWEY): Initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany[J]. Sleep Med, 2023, 103: 138-143. |
| [32] | Shellenberg TP, Stoops WW, Lile JA, et al. An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations[J]. Expert Rev Clin Pharmacol, 2020, 13(8): 825-833. |
| [33] | Merrill M. Mitler RS, Roza Hajdukovich, et al. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline[J]. Sleep, 1986, 9(1): 260-264. |
| [34] | Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications[J]. Sleep Med, 2020, 68: 97-109. |
| [35] | Beckmann D, Lowman KL, Nargiso J, et al. Substance-induced psychosis in youth[J]. Child Adolesc Psychiatr Clin N Am, 2020, 29(1): 131-143. |
| [36] | Man KKC, H?ge A, Banaschewski T, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study[J]. Lancet Psychiatry, 2023, 10(5): 323-333. |
| [37] | Zhang X, Berridge MS, Apana SM, et al. Discontinuation of methylphenidate after long-term exposure in nonhuman primates[J]. Neurotoxicol Teratol, 2023, 97: 107173. |
| [38] | Jin L, Shi L, Zhang Y, et al. Antidepressants for the treatment of narcolepsy: a prospective study of 148 patients in northern China[J]. J Clin Neurosci, 2019, 63: 27-31. |
| [39] | Ratkiewicz M, Splaingard M. Treatment of cataplexy in a three-year-old using venlafaxine[J]. J Clin Sleep Med, 2013, 09(12): 1341-1342. |
| [40] | M?ller LR?, John R. Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations[J]. J Child Adolesc Psychopharmacol, 2009, 19(2): 197-201. |
| [41] | Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy[J]. J Neurol Neurosurg Psychiatry, 1980, 43(2): 171-174. |
| [42] | Larrosa O, de la Llave Y, Bario S, et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study[J]. Sleep, 2001, 24(3): 282-285. |
| [43] | Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study[J]. Neurology, 1994, 44: 707-709. |
| [44] | Fonseca Hde A, Lopes DA, Pereira D, et al. The use of citalopram for the treatment of cataplexy[J]. Sleep Sci, 2014, 7(1): 50-52. |
| [45] | Huang YS, Guilleminault C. Narcolepsy: action of two γ-aminobutyric acid type B agonists, baclofen and sodium oxybate[J]. Pediatr Neurol, 2009, 41(1): 9-16. |
| [46] | Dhafar HO, BaHammam AS. Body weight and metabolic rate changes in narcolepsy: current knowledge and future directions[J]. Metabolites, 2022, 12(11): 1120. |
| [47] | Melzi S, Prevot V, Peyron C. Precocious puberty in narcolepsy type 1: Orexin loss and/or neuroinflammation, which is to blame?[J]. Sleep Med Rev, 2022, 65: 101683. |
| [48] | Valizadeh P, Momtazmanesh S, Plazzi G, et al. Connecting the dots: an updated review of the role of autoimmunity in narcolepsy and emerging immunotherapeutic approaches[J]. Sleep Med, 2024, 113: 378-396. |
| [49] | Lecendreux M, Berthier J, Corny J, et al. Intravenous immunoglobulin therapy in pediatric narcolepsy: a nonrandomized, open-label, controlled, longitudinal sbservational dtudy[J]. J Clin Sleep Med, 2017, 13(3): 441-453. |
| [50] | Chen W, Black J, Call P, et al. Late-Onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis[J]. Ann Neurol, 2005, 58(3): 489-490. |
| [51] | Pincherle A, Villani F, Ferini Strambi L, et al. Immuno-adsorption for the treatment of narcolepsy with cataplexy[J]. Neurol Sci, 2008, 29(6): 499-500. |
| [52] | Weinhold SL, Seeck-Hirschner M, Nowak A, et al. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy[J]. Behav Brain Res, 2014, 262: 8-13. |
| [53] | Ishikawa T, Hara H, Kawano A, et al. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model[J]. Pharmacol Biochem Behav, 2022, 220: 173464. |
| [54] | Evansa R, Kimura H, Alexander R, et al. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients[J]. Proc Natl Acad Sci U S A, 2022, 119(35): e2207531119. |
| [55] | Yamada R, Narita N, Ishikawa T, et al. The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys[J]. Pharmacol Biochem Behav, 2024, 234: 173690. |
| [56] | Dauvilliers Y, Mignot E, del Río Villegas R, et al. Oral orexin receptor 2 agonist in narcolepsy type 1[J]. N Engl J Med, 2023, 389(4): 309-321. |
| [57] | Mitsukawa K, Terada M, Yamada R, et al. TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models[J]. Sci Rep, 2024, 14(1): 20838. |
/
| 〈 |
|
〉 |
